Improving Treatment Success Rates for Type 2 Diabetes: Recommendations for a Changing Environment

被引:0
|
作者
Triplitt, Curtis [1 ,2 ]
机构
[1] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78207 USA
[2] Texas Diabet Inst, San Antonio, TX USA
来源
AMERICAN JOURNAL OF MANAGED CARE | 2010年 / 16卷 / 07期
关键词
INITIAL COMBINATION THERAPY; SITAGLIPTIN; METFORMIN; ADHERENCE; INSULIN; ACHIEVEMENT; EXENATIDE; EFFICACY; SAFETY; ADULTS;
D O I
暂无
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
As demonstrated by suboptimal levels of therapeutic goal achievement, there exists significant room for improvement in type 2 diabetes management. Despite widespread disease awareness and high rates of risk-factor testing in managed care, effective metabolic control in patients with type 2 diabetes is lacking and points toward a phenomenon known as clinical inertia. Clinical inertia, defined as a failure to initiate or advance therapy in a patient who is not at the evidence-based goal, is a key contributing factor in the suboptimal rates of therapeutic target achievement for type 2 diabetes. The causes of clinical inertia are multifactorial and interactive, arising among patients, providers, and health systems and from specific characteristics of available treatments. Therapeutic nonadherence is perhaps the most significant factor contributing to clinical inertia, with recent analyses demonstrating that providers are more likely to prescribe a dose escalation in patients who are adherent to therapy compared with those who are not. While the concept may be counterintuitive, antihyperglycemic agents also have the potential to cause or contribute to the phenomenon of clinical inertia. This often occurs via factors inherent to the drugs themselves, such as treatment-related adverse effects (eg, hypoglycemia, weight gain, edema, gastrointestinal symptoms), perception of long-term safety profiles, and the complexity of the treatment regimen. Often not considered, but equally important, is the durability of an antihyperglycemic agent to maintain glycosylated hemoglobin (A1C) level goals. Because no monotherapy exists to arrest the pancreatic beta-cell failure of type 2 diabetes, early combination therapy with thiazolidinediones and glucagon-like protein-1 agonists that is associated with sustained A1C level reduction is the only hope to change the progressive nature of type 2 diabetes mellitus. (Am J Manag Care. 2010; 16: S195-S200)
引用
收藏
页码:S195 / S200
页数:6
相关论文
共 50 条
  • [41] Dietary recommendations and treatment options for patients with type II diabetes
    Müller, UA
    Müller, R
    [J]. MEDIZINISCHE WELT, 2000, 51 (03): : 52 - 58
  • [42] Changing Trends in Type 2 Diabetes Mellitus Treatment Intensification, 2002-2010
    McCoy, Rozalina G.
    Zhang, Yuanhui
    Herrin, Jeph
    Denton, Brian T.
    Mason, Jennifer E.
    Montori, Victor M.
    Smith, Steven A.
    Shah, Nilay D.
    [J]. AMERICAN JOURNAL OF MANAGED CARE, 2015, 21 (05): : E288 - +
  • [43] German Diabetes Society New Nutritional Recommendations for Type 2 Diabetes
    不详
    [J]. ERNAHRUNGS UMSCHAU, 2022, 69 (02): : M62 - M62
  • [44] Gene-Environment and Gene-Treatment Interactions in Type 2 Diabetes
    Franks, Paul W.
    Pearson, Ewan
    Florez, Jose C.
    [J]. DIABETES CARE, 2013, 36 (05) : 1413 - 1421
  • [45] Nutritional Recommendations for the Prevention of Type 2 Diabetes Mellitus
    Skurk, Thomas
    Gruenerbel, Arthur
    Hummel, Sandra
    Kabisch, Stefan
    Keuthage, Winfried
    Muessig, Karsten
    Nussbaumer, Helmut
    Rubin, Diana
    Simon, Marie-Christine
    Tombek, Astrid
    Weber, Katharina S.
    [J]. EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2024, 132 (02) : 68 - 82
  • [46] Dietary recommendations for persons with type 2 diabetes mellitus
    Skurk, Thomas
    Bosy-Westphal, Anja
    Gruenerbel, Arthur
    Kabisch, Stefan
    Keuthage, Winfried
    Kronsbein, Peter
    Muessig, Karsten
    Nussbaumer, Helmut
    Pfeiffer, Andreas F. H.
    Simon, Marie-Christine
    Tombek, Astrid
    Weber, Katharina S.
    Rubin, Diana
    [J]. DIABETOLOGIE, 2024, 20 (03): : 425 - 456
  • [47] Nutritional Recommendations for People with Type 2 Diabetes mellitus
    Skurk, Thomas
    Bosy-Westphal, Anja
    Gruenerbel, Arthur
    Kabisch, Stefan
    Keuthage, Winfried
    Kronsbein, Peter
    Mussig, Karsten
    Nussbaumer, Helmut
    Pfeiffer, Andreas F. H.
    Simon, Marie-Christine
    Tombek, Astrid
    Weber, Katharina S.
    Rubin, Diana
    [J]. DIABETOLOGIE UND STOFFWECHSEL, 2022, 17 : S256 - S290
  • [48] Dietary recommendations for persons with type 2 diabetes mellitus
    Skurk, Thomas
    Bosy-Westphal, Anja
    Gruenerbel, Arthur
    Kabisch, Stefan
    Keuthage, Winfried
    Kronsbein, Peter
    Muessig, Karsten
    Nussbaumer, Helmut
    Pfeiffer, Andreas F. H.
    Simon, Marie-Christine
    Tombek, Astrid
    Weber, Katharina S. S.
    Rubin, Diana
    [J]. DIABETOLOGIE, 2023, 19 (04): : 482 - 512
  • [49] Dietary Recommendations for Persons with Type 2 Diabetes Mellitus
    Skurk, Thomas
    Bosy-Westphal, Anja
    Gruenerbel, Arthur
    Kabisch, Stefan
    Keuthage, Winfried
    Kronsbein, Peter
    Muessig, Karsten
    Nussbaumer, Helmut
    Pfeiffer, Andreas F. H.
    Simon, Marie-Christine
    Tombek, Astrid
    Weber, Katharina S.
    Rubin, Diana
    [J]. EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2024, 132 (04) : 182 - 215
  • [50] Nutritional recommendations for people with type 2 diabetes mellitus
    Skurk, Thomas
    Bosy-Westphal, Anja
    Gruenerbel, Arthur
    Kabisch, Stefan
    Keuthage, Winfried
    Kronsbein, Peter
    Muessig, Karsten
    Nussbaumer, Helmut
    Pfeiffer, Andreas F. H.
    Simon, Marie-Christine
    Tombek, Astrid
    Weber, Katharina S.
    Rubin, Diana
    Ausschuss Ernahrung DDG
    [J]. DIABETOLOGIE UND STOFFWECHSEL, 2023, 18 : S270 - S304